Live blog
Status: 07/09/2021 5:21 a.m.
The RKI reported 949 new infections in the morning. The seven-day incidence is 5.5. Pfizer and BioNTech plan to apply for approval for a third dose of vaccine in the US and Europe soon. All developments in the live blog.
05:21 am
According to the manufacturer, the Cuban corona vaccine is 91.2 percent effective
The corona vaccine from the Cuban manufacturer Finlay de Vacunas is highly effective. “We were able to develop a vaccine with 91.2 percent effectiveness,” said the head of the research institute, Vicente Vérez, on Cuban television. Accordingly, three vaccine doses are necessary for this comprehensive protection against the coronavirus. The official news portal Cubadebate, citing the research institute Finlay, reported that the vaccine prevents symptoms of Covid-19 by 91.2 percent. In 75.5 percent of cases, it protects against infection and 100 percent against serious illnesses and death as a result of an infection.
05:02 am
RKI reports 949 new infections – incidence at 5.5
The seven-day incidence of corona infections increased on the third day in a row. It was 5.5 new infections in seven days per 100,000 inhabitants. For comparison: a day ago it was 5.2, two days ago it was 5.1. The health authorities in Germany reported 949 new corona infections to the Robert Koch Institute within one day. For comparison: a week ago the value was 649 infections. According to the new information, 49 deaths were recorded across Germany within 24 hours. A week ago there were 69 deaths. The RKI has counted 3,734,468 detected infections with Sars-CoV-2 since the beginning of the pandemic.
05:02 am
Pfizer and BioNTech plan to apply for third dose approval
Vaccine manufacturers BioNTech and Pfizer plan to apply for approval to administer a third dose of their corona vaccine soon. The two companies plan to submit corresponding data “in the coming weeks” to the US FDA, the European Medicines Agency Ema and other regulatory authorities. “Although protection against serious illness remains high for six months, efficacy against symptomatic cases can be expected to decrease over time and variants to emerge,” the two companies said. Therefore, a third dose may be required six to twelve months after the first vaccination.